Evidence map›Paper›PMID 23530302›Full record

ArticleEthnicity & disease2013

Validation of the Kidney Disease Quality of Life Short Form 36 (KDQOL-36) US Spanish and English versions in a cohort of Hispanics with chronic kidney disease.

Ana C Ricardo, Eileen Hacker, Claudia M Lora, Lynn Ackerson, Karen B DeSalvo, Alan Go, John W Kusek, Lisa Nessel, Akinlolu Ojo, Raymond R Townsend and 4 more

2 registry-linked trialsAbstract readValidation Study
In one paragraph

Article in Ethnicity & disease, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 48 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
48citing papers in PubMed, 2 pooled it
1.4field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00304148 active not recruitingnot on this map

Prospective Cohort Study of Chronic Renal Insufficiency

TypeobservationalSponsorUniversity of PennsylvaniaRan2003 to 2028Enrolled5,499ConditionsRenal Insufficiency, Chronic
NCT06466421 phase4completednot on this mapstarted 2024, after this paper: background citation

Clinical Study to Compare The Safety and Possible Efficacy of Fexofenadine Versus Gabapentin for Uremic Pruritus in Patients on Regular Hemodialysis

TypeinterventionalSponsorTanta UniversityRan2024 to 2024Enrolled60ConditionsUremic Pruritus, Chronic Kidney Disease-associated Pruritus, Hemodialysis, End-stage Renal DiseaseArmsFexofenadine, Gabapentin
3 · Its place in the literature

Who cites it

48 citing papers in PubMed, 2 syntheses or guidelines pooled it, 71 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Trial
  5. Trial
  6. Article
  7. Article
  8. Article
  9. Article
  10. Observational
  11. Article
  12. Validation of the Beck Depression Inventory in US Hispanic Patients with CKD.Clinical journal of the American Society of Nephrology : CJASN · 2025
    Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Identification and Management of CKD-Associated Pruritus: Current Insights.International journal of nephrology and renovascular disease · 2024
    Review
  18. Depression and incident cardiovascular disease among patients with chronic kidney disease.International journal of cardiology. Cardiovascular risk and prevention · 2023
    Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 1 institution in 1 country.

Ana C RicardoDepartment of Medicine, Section of Nephrology, University of Illinois at Chicago, USA. aricar2@uic.edu
Eileen Hacker
Claudia M Lora
Lynn Ackerson
Karen B DeSalvo
Alan Go
John W Kusek
Lisa Nessel
Akinlolu Ojo
Raymond R Townsend
Dawei Xie
Carol E Ferrans
James P Lash
CRIC Investigators
University of Illinois Chicago · US

Funding

UCSF CLINICAL AND TRANSLATIONAL SCIENCE INSTITUTEUL1RR024131 · NCRR · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI JOHNSTON, S. CLAIBORNE · 2006 to 2011
$111.2M
Institute for Clinical and Translational Research (UL1)UL1RR025005 · NCRR · JOHNS HOPKINS UNIVERSITY · PI FORD, DANIEL ERNEST · 2007 to 2011
$75.8M
INSTITUTIONAL CLINICAL AND TRANSLATIONAL SCIENCE AWARDUL1RR024134 · NCRR · UNIVERSITY OF PENNSYLVANIA · PI FITZGERALD, GARRET A · 2006 to 2011
$70.4M
MICHIGAN INSTITUTE FOR CLINICAL AND HEALTH RESEARCH (MICHR) (UL1): (BPCA)UL1RR024986 · NCRR · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI SHANLEY, THOMAS P. · 2007 to 2011
$51.2M
Scientific and Data Coordinating Center(SDCC) for the P*U01DK060990 · NIDDK · UNIVERSITY OF PENNSYLVANIA · PI FELDMAN, HAROLD I · 2001 to 2017
$50.1M
Clinical and Translational Science Collaborative of ClevelandUL1TR000439 · NCATS · CASE WESTERN RESERVE UNIVERSITY · PI KONSTAN, MICHAEL W. · 2012 to 2016
$50.0M
ZINC GLUCONATE GLYCINE LOZENGES &VITAMIN C EFFECTS ON COMMON COLDM01RR000042 · NCRR · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI ORAL, ELIF ARIOGLU · 1985 to 2007
$40.8M
Zonulin Antibodies in Intestinal Permeabilitiy in IDDMM01RR016500 · NCRR · UNIVERSITY OF MARYLAND BALTIMORE · PI GAROFALO, MICHAEL CURTIS · 2002 to 2009
$20.2M
Study of the Care and Outcomes of REnal InsufficiencyU01DK060902 · NIDDK · KAISER FOUNDATION RESEARCH INSTITUTE · PI GO, ALAN S · 2001 to 2025
$19.5M
Limited Competition for the Continuation of the Chronic Renal Insufficiency CohorU01DK061021 · NIDDK · CASE WESTERN RESERVE UNIVERSITY · PI RAHMAN, MAHBOOB · 2001 to 2025
$17.3M
Prospective Renal Insufficiency Cohort Evaluation:PRICEU01DK060984 · NIDDK · UNIVERSITY OF PENNSYLVANIA · PI COHEN, DEBBIE L · 2001 to 2025
$17.0M
Prospective Cohort Study of Chronic Renal InsufficiencyU01DK061028 · NIDDK · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI RAO, PANDURANGA S · 2001 to 2025
$16.9M
NCATS NIH HHS UL1 TR000439NCATS NIH HHS UL1TR000439NCRR NIH HHS M01 RR-000042NCRR NIH HHS M01 RR000042NCRR NIH HHS M01 RR013987NCRR NIH HHS M01 RR016500NCRR NIH HHS M01 RR-16500NCRR NIH HHS UL1 RR-024131NCRR NIH HHS UL1 RR024131NCRR NIH HHS UL1 RR-024134NCRR NIH HHS UL1 RR024134NCRR NIH HHS UL1 RR-024986NCRR NIH HHS UL1 RR024986NCRR NIH HHS UL1 RR-025005NCRR NIH HHS UL1 RR025005NCRR NIH HHS UL1 RR029879NCRR NIH HHS UL1RR029879NIDDK NIH HHS K23 DK094829NIDDK NIH HHS K24 DK092290NIDDK NIH HHS R01 DK072231NIDDK NIH HHS R56 DK072231NIDDK NIH HHS U01 DK060902NIDDK NIH HHS U01DK060902NIDDK NIH HHS U01 DK060963NIDDK NIH HHS U01DK060963NIDDK NIH HHS U01 DK060980NIDDK NIH HHS U01DK060980NIDDK NIH HHS U01 DK060984NIDDK NIH HHS U01DK060984NIDDK NIH HHS U01 DK060990NIDDK NIH HHS U01DK060990NIDDK NIH HHS U01 DK061021NIDDK NIH HHS U01DK061021NIDDK NIH HHS U01 DK061022NIDDK NIH HHS U01DK061022NIDDK NIH HHS U01 DK061028NIDDK NIH HHS U01DK061028
6 · The paper itself

Abstract

objectiveEvaluate the reliability and validity of the Kidney Disease Quality of Life Short Form 36 (KDQOL-36) in Hispanics with mild-to-moderate chronic kidney disease (CKD).

designCross-sectional

settingChronic Renal Insufficiency Cohort Study

participants420 Hispanic (150 English- and 270 Spanish-speakers), and 409 non-Hispanic White individuals, matched by age (mean 57 years), sex (60% male), kidney function (mean estimated glomerular filtration rate 36ml/min/1.73m2), and diabetes (70%).

methodsTo measure construct validity, we selected instruments, comorbidities, and laboratory tests related to at least one KDQOL-36 subscale. Reliability was determined by calculating Cronbach's alpha.

resultsReliability of each KDQOL-36 subscale [SF-12 Physical Component Summary (PCS) and Mental Component Summary (MCS), Symptoms/Problems, Burden of Kidney Disease and Effects of Kidney Disease] was very good (Cronbach's alpha >0.8). Construct validity was supported by expected negative correlation between MCS scores and the Beck Depression Inventory in all three subgroups (r=-0.56 to -0.61, P<.0001). There was inverse correlation between the Symptoms/ Problems subscale and the Patient Symptom Form (r= -0.70 to -0.77, P<.0001). We also found significant, positive correlation between the PCS score and a physical activity survey (r=+0.29 to +0.38, P< or =.003); and between the PCS and MCS scores and the Kansas City Questionnaire (r= +0.31 to +0.64, P<.0001). Reliability and validity were similar across all racial/ethnic groups analyzed separately.

conclusionOur findings support the use of the KDQOL-36 as a measure of HRQOL in this cohort of US Hispanics with CKD.

Indexed as

Quality of LifeRenal Insufficiency, ChronicAgedCohort StudiesCross-Sectional StudiesFemaleHealth Status IndicatorsHumansLanguageMaleMiddle AgedUnited States

Identifiers

PMID23530302
PMCPMC3651651
OpenAlexW193406042

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.